Participated · Seed · Jul 2026

Immitra Bio is developing scalable, one-time curative in-vivo gene editing therapies built around a mutation-agnostic editing approach and a digital target discovery platform. Its lead candidate, IB-003, is being developed as a potential one-time curative in-vivo gene editing treatment for an inherited anemia. The company's approach is designed to avoid complex ex-vivo cell manipulation, patient conditioning, and stem cell transplantation, aiming to enable off-the-shelf formulations that treat all patients within a given disease regardless of underlying mutation. Immitra Bio says its platform could generate dozens of differentiated therapeutic assets more quickly than highly personalized approaches. The recent CHF 2.4 million pre-seed financing will primarily fund preclinical proof-of-concept work for IB-003 and support additional discovery and validation across the pipeline and platform refinement. The company highlights scalability and commercial viability as core objectives for its technology.

Led · Equity · Jul 2026

goNEON Agentic Systems develops an agentic AI platform that automatically generates technically feasible, regulation-compliant infrastructure designs based on engineering requirements, local regulations, and real‑world constraints. The technology is intended to accelerate planning by producing and evaluating multiple design alternatives in minutes rather than the weeks or months required by traditional manual workflows. The company was spun out of ETH and is led by CEO Raphael Eder and CTO Dr Lukas Ballo. With the Venture Kick funding, goNEON plans to prioritise pilot projects, productise repeatable planning workflows into scalable modules, and validate the use cases that will underpin its broader infrastructure planning platform. The article does not disclose revenue, user metrics, or prior external funding. The team positions the platform as a decision-support tool that augments rather than replaces engineers by speeding up scenario generation and compliance checking.

Led · Equity · Jul 2026

RAROG develops a portable detection system that identifies radio signals emitted by everyday electronic devices such as smartphones, smartwatches and fitness trackers, operating independently of mobile networks or external infrastructure. The technology can detect people through vegetation, fog, snow and rubble, and is already being deployed in mountain rescue operations in places like the Wicklow Mountains and the Swiss Alps. RAROG is expanding its target users to include firefighters, civil protection units and other emergency response services. The company positions its system as a way to turn ordinary personal electronics into effective rescue beacons to speed searches and improve outcomes. With the Venture Kick funding, RAROG plans to finalise product development, complete CE marking, manufacture an initial production batch and enter the market with a growing team. No revenue or user metrics were disclosed in the article.

Led · Equity · Jul 2026

Founded in 2025 and based in Schlieren, ALP Bio is building a hybrid platform that combines human tonsil-derived immune organoid readouts with generative AI to predict and reduce anti-drug antibody risk earlier in antibody discovery and development. The platform is designed to support lead candidate screening, ADA risk stratification, and sequence optimisation while preserving therapeutic function. ALP Bio emphasizes integrating experimentally measured human immune biology with machine learning models to bring more clinically relevant signal into earlier decision-making. The team plans to scale lab automation and throughput and pursue early partner projects with pharmaceutical and biotech teams. Financially, the company recently completed a €1.9 million pre-Seed round to fund platform expansion and commercial engagement in Switzerland and the US.

Led · Equity · Jun 2026

nureo is developing generative, automated 3D design software that transforms user specifications and constraints into production-ready geometries, aiming to reduce manual modelling effort by up to 90%. Its platform enables engineers to generate designs tailored to different applications and manufacturing methods, improving productivity and shortening iteration cycles. Early customers include industrial OEMs and SMEs such as machine builders, component manufacturers, and engineering service providers. The company is focused on converting pilot projects into recurring revenue while accelerating product development and commercial scaling. To support these goals, nureo plans to grow its engineering and business development teams and increase its presence at international trade fairs and conferences. The article does not provide revenue or user metrics.